Rostaquo S.P.A.
Records under this name other than patents Rostaquo S.P.A. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 5 of 5 · Back to Rostaquo S.P.A.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,868,757 | 5-β, 14-β-androstane derivatives useful for the treatment of proteinuria, glomerulosclerosis and renal failure Formerly held Lapsed on the fee record Ended Jan 16, 2026 · USPTO record | Lapsed on the fee record | Ended Jan 16, 2026 | USPTO record |
| US 9,408,854 | Methods and systems for pharmacogenomic treatment of cardiovascular conditions Formerly held Lapsed on the fee record Ended Aug 9, 2024 · USPTO record | Lapsed on the fee record | Ended Aug 9, 2024 | USPTO record |
| US 9,127,037 | Crystalline rostafuroxin Formerly held Lapsed on the fee record Ended Sep 8, 2023 · USPTO record | Lapsed on the fee record | Ended Sep 8, 2023 | USPTO record |
| US 5,567,697 | 17-(4-Pyridazinyl) -5.beta., 14.beta.-androstane derivatives active on the cardiovascular system, processes for their preparation and pharmaceutical compositions containing same Term ended Term ended no later than Oct 22, 2016 · Low confidence | Term ended | Term ended no later than Oct 22, 2016 | Low confidence |
| US 5,591,734 | 17-(3-Furyl)-5.beta., 14.beta.-androstane derivatives active on the cardiovascular system, processes for their preparation and pharmaceutical compositions containing same Term ended Term ended no later than Jan 7, 2017 · Low confidence | Term ended | Term ended no later than Jan 7, 2017 | Low confidence |